Shortly following the news on FDA's "breakthrough therapy" designation and the 12-week clinical durability data on its LSD therapy for generalized anxiety, psychedelics biotech MindMed (NASDAQ:MNMD) announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 each.

The company has also entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares, at an individual price of $6.00. All these shares are being sold by MindMed to new investors Deep Track Capital and Commodore Capital.

Meanwhile, the underwritten offering reportedly includes participation from new investors Ally Bridge...